PureWick Corporation

PureWick Corporation has been granted 63 US utility patents between 2019 and 2025, placing PureWick Corporation at rank #5,461 across all assignees tracked by PlainPatent. This portfolio spans 13 distinct Cooperative Patent Classification (CPC) subclasses, averaging 17.6 claims per patent with primary concentration in A61F (FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICE). As a US Corporation, PureWick Corporation is one of the more focused assignees in the PatentsView dataset. The composite Innovation Score of 52.5/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.

Filing cadence tells the strategic story. Between 2020 and 2025 the company received 59 grants, compared with 4 in the 2015–2019 window — a +1375% shift in five-year velocity. An acceleration of this magnitude signals aggressive R&D investment and expanding technical ambition. The US Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.

Claim depth and technology breadth together indicate competitive posture. PureWick Corporation's 17.6 average claims per patent sits within the typical range for solid legal coverage without excessive prosecution cost, while concentration in 13 subclasses points to a focused technical program. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark PureWick Corporation against peers pursuing similar technology classes.